Carly Helfand

Biography for Carly Helfand

Carly Helfand, News Editor

Carly Helfand is a news editor with Fierce's life sciences group, writing for FiercePharma, FiercePharmaMarketing and FierceVaccines. Carly got her start covering pharma while earning her master’s at Northwestern University’s Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post’s “Wonkblog” and Cape Town’s Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at chelfand@fiercemarkets.com and follow her on Twitter at @CarlyHFierce.

Articles by Carly Helfand

Pfizer scores new Prevenar indication in Europe

Pfizer's Prevenar 13 is already the world's best-selling vaccine, and it kept on rolling Tuesday with a European label expansion.

With 77 layoffs, Valeant gets to work squeezing costs from Dendreon

It's no secret that when serial acquirer and cost-cutting enthusiast Valeant takes over a company, layoffs are on the way. And for Dendreon, the bankrupt Seattle biotech whose assets the Canadian snatched up last month, they've already begun.

Pfizer, Novartis get MenB ACIP nod--but not the one they're really after

Pfizer and Novartis officially have a nod from the CDC's Advisory Committee on Immunization Practices (ACIP) for their recently approved meningitis B vaccines. Problem is, it doesn't cover nearly as large a population as the pharma giants would like.

Valeant touts PhII Provenge data following Dendreon buy

Valeant only just picked up Provenge and other assets from bankrupt Dendreon, but it's already trumpeting positive preliminary data for the flailing cancer vaccine. On Wednesday, it announced Phase II results showing that the immune response from Provenge continues two years after biochemically recurrent prostate cancer patients complete treatment.

NewLink nets $20M Ebola milestone from Merck

NewLink's Ebola vaccine tie-up with Merck continues to pay off.

Takeda places vaccines unit in Singapore to push for global growth

Last September, Takeda announced it would be putting vaccines into their own specialty business unit to "accelerate the globalization" of the business. And now, it's positioning the unit geographically to do the same.

Pfizer trumpets positive Trumenba data ahead of ACIP vote

Pfizer may have FDA approval for meningitis B vaccine Trumenba, but it can only take the jab so far without a nod from the CDC's Advisory Committee on Immunization Practices (ACIP). Now, though, it's got some positive new data on the shot just in time to help it make its case for one.

HIV vaccine trial kicks off in South Africa

Researchers have launched a clinical trial in South Africa--dubbed HVTN 100--to evaluate a candidate HIV vaccine regimen for safety and the immune response it triggers.

Advaxis nets $23M in financing for cancer vaccine development

Advaxis is pushing full steam ahead to test its cancer vaccine candidates in immunotherapy combos, and it just scored another $23 million to help its hopefuls through the clinic.

VaxInnate reaps $53M for flu jab trials on BARDA contract extension

The U.S. Department of Health and Human Services apparently likes what it's seen from a 5-year contract with VaxInnate. Its Biomedical Advanced Research and Development Authority (BARDA) has extended the contract's base period with the flu vaccine maker, a move that allows for the use of $53 million.